Trial Profile
A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pateclizumab (Primary) ; Adalimumab; Leflunomide; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2012 Planned End Date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 24 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.